Is Avicanna Inc. (AVCNF) a Buy, Sell, or Hold?
OTC : AVCNF
Avicanna Inc. — News
$0.095 USD
$0.0 (-1.04%)
- Volume
- 38K
- Average Volume
- 91.92K
- Market Capitalization
- $11.95M
- P/E Ratio
- -4.25
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.24
- Year Low
- $0.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.96
| Source | Headline |
|---|---|
|
Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio
Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats globenewswire.com - 2026-07-16 07:30:00 |
|
Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer
TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC. globenewswire.com - 2026-06-30 17:30:00 |
|
Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare
FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products. globenewswire.com - 2026-06-15 08:30:00 |
|
Avicanna Announces Closing of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, June 12, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private placement offering of 4,000,014 units of the Company (“Units”) at a price of $0.15 per Unit for aggregate gross proceeds of $600,002.1 (“Offering”). globenewswire.com - 2026-06-12 17:30:00 |
|
Avicanna Reports Q1 2026 Financial Statements
Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform globenewswire.com - 2026-05-14 07:30:00 |
